Table 3.
Major Interventional Studies for ARAS and FMD
| Study | Year | Patients | Type | Follow‐Up | Objective | Results |
|---|---|---|---|---|---|---|
| ARAS studies | ||||||
| Dorros et al28 | 1998 | 163 | Prospective | 4 years | To evaluate PTA/stenting in ARAS | Benefit |
| van Jaarsveld et al34 | 2000 | 106 | RCT | 1 year | To compare PTA vs medical treatment in ARAS | No benefit |
| Dorros et al29 | 2002 | 1058 | Prospective | 4 years | To evaluate PTA/stenting in ARAS | Benefit |
| Zeller et al30 | 2003 | 241 | Prospective | 5 years | To evaluate PTA/stenting in ARAS | Benefit |
| Zeller et al31 | 2004 | 340 | Prospective | 6 years | To evaluate PTA/stenting in ARAS | Benefit |
| Wheatley et al32 | 2009 | 806 | RCT | 5 years | To compare medical treatment vs medical treatment plus PTA/stenting in ARAS | No benefit |
| Bax et al33 | 2009 | 140 | RCT | 2 years | To evaluate PTA/stenting in ARAS | No benefit |
| FMD studies | ||||||
| Mousa et al35 | 2012 | 35 | Retrospective | 1 year | To evaluate PTA/stenting in renal FMD | Benefit |
| Gavalas et al36 | 2014 | 29 | Prospective | 2–5 years | To evaluate PTA in renal FMD | Benefit |
| Fujihara et al37 | 2014 | 22 | Retrospective | 6 years | To evaluate PTA in renal FMD | Benefit |
Abbreviations: ARAS, atherosclerotic renal artery stenosis; FMD, fibromuscular dysplasia; PTA, percutaneous transluminal angioplasty; RCT, randomized controlled trial.